☆ 4.7 Article

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

ANNALS OF ONCOLOGY (2017)

Get Full Text
Add to Collection

Journal

ANNALS OF ONCOLOGY
Volume 28, Issue -, Pages 1-21

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdx222

Keywords

-

Categories

Oncology

Funding

  1. Merck Sharp Dohme
  2. Boehringer Ingelheim
  3. Pfizer
  4. Celgene
  5. AstraZeneca
  6. Bristol-Myers Squibb
  7. Eli Lilly
  8. Merck KGaA
  9. Merck Sharpe Dohme
  10. Novartis
  11. Roche
  12. Roche Diagnostics
  13. Varian Medical Systems

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.